Simone Hettmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7999228/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combinatorial effects of azacitidine and trametinib on <i>NRAS</i> â€mutated melanoma. Pediatric Blood and Cancer, 2022, 69, e29468.	1.5	6
2	Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. European Journal of Cancer, 2022, 168, 56-64.	2.8	8
3	ATRT-09. Outcome and therapeutic interventions in relapsed and refractory ATRT – The EU-RHAB perspective. Neuro-Oncology, 2022, 24, i4-i4.	1.2	2
4	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. European Journal of Cancer, 2022, 172, 367-386.	2.8	19
5	Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 327-336.	1.9	13
6	Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2021, 68, e28798.	1.5	38
7	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. Oncology Research and Treatment, 2021, 44, 301-312.	1.2	13
8	Lack of Electron Acceptors Contributes to Redox Stress and Growth Arrest in Asparagine-Starved Sarcoma Cells. Cancers, 2021, 13, 412.	3.7	1
9	Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. British Journal of Cancer, 2021, 124, 1637-1646.	6.4	12
10	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 2021, 13, 1151.	3.7	27
11	Negative correlation of single-cell <i>PAX3:FOXO1</i> expression with tumorigenicity in rhabdomyosarcoma. Life Science Alliance, 2021, 4, e202001002.	2.8	4
12	Abstract 3122: Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma. , 2021, , .		0
13	Abstract 275: Lack of electron acceptors contributes to redox stress and growth arrest in asparagine-starved sarcoma cells. , 2021, , .		0
14	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatric Blood and Cancer, 2021, 68, e29267.	1.5	7
15	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
16	Breast cancer characteristics and surgery among women with Liâ€Fraumeni syndrome in Germany—A retrospective cohort study. Cancer Medicine, 2021, 10, 7747-7758.	2.8	7
17	In Reply: Comments About Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. Journal of Pediatric Hematology/Oncology, 2021, 43, 116-117.	0.6	0
18	Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatric Blood and Cancer, 2020, 67, e28095.	1.5	5

SIMONE HETTMER

#	Article	IF	CITATIONS
19	Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. European Journal of Cancer, 2020, 137, 183-192.	2.8	28
20	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
21	Case Report: Hepatic Adenoma in a Child With a Congenital Extrahepatic Portosystemic Shunt. Frontiers in Pediatrics, 2020, 8, 501.	1.9	3
22	Growth inhibition associated with disruption of the actin cytoskeleton by Latrunculin A in rhabdomyosarcoma cells. PLoS ONE, 2020, 15, e0238572.	2.5	6
23	Dermatofibrosarcoma protuberans in children and adolescents: Primary and Relapsed disease—Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS). Journal of Surgical Oncology, 2020, 122, 263-272.	1.7	6
24	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer, 2020, 126, 4032-4041.	4.1	20
25	Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. Journal of Pediatric Hematology/Oncology, 2020, 42, e265-e270.	0.6	5
26	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
27	Title is missing!. , 2020, 15, e0238572.		0
28	Title is missing!. , 2020, 15, e0238572.		0
29	Title is missing!. , 2020, 15, e0238572.		0
30	Title is missing!. , 2020, 15, e0238572.		0
31	Title is missing!. , 2020, 15, e0238572.		Ο
32	Title is missing!. , 2020, 15, e0238572.		0
33	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer, 2019, 66, e27869.	1.5	57
34	Myxoid liposarcoma: it's a hippo's world. EMBO Molecular Medicine, 2019, 11, .	6.9	3
35	RhabdomyosarcomaÂdiagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatric Blood and Cancer, 2019, 66, e27652.	1.5	17
36	Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open, 2019, 4, e000583.	4.5	22

#	Article	IF	CITATIONS
37	Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion–negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2018, 124, 1973-1981.	4.1	14
38	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
39	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precision Oncology, 2018, 2, 1-16.	3.0	41
40	Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma. Scientific Reports, 2018, 8, 15674.	3.3	9
41	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
42	Epithelioid hemangioendotheliomas of the liver and lung in children and adolescents. Pediatric Blood and Cancer, 2017, 64, e26675.	1.5	31
43	An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Populationâ€Based Evidence for a Cancer Predisposition Syndrome?. Pediatric Blood and Cancer, 2016, 63, 196-201.	1.5	35
44	Second malignancy risk among pediatric, adolescent, and young adult survivors of fusionâ€positive and fusionâ€negative sarcomas: Results from the SEER database, 1992 through 2012. Cancer, 2016, 122, 3492-3500.	4.1	7
45	Hedgehog-driven myogenic tumors recapitulate skeletal muscle cellular heterogeneity. Experimental Cell Research, 2016, 340, 43-52.	2.6	3
46	Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Medicine, 2015, 4, 781-790.	2.8	25
47	Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. ELife, 2015, 4, .	6.0	56
48	Distinct Malignant Behaviors of Mouse Myogenic Tumors Induced by Different Oncogenetic Lesions. Frontiers in Oncology, 2015, 5, 50.	2.8	3
49	Myogenic Tumors in Nevoid Basal Cell Carcinoma Syndrome. Journal of Pediatric Hematology/Oncology, 2015, 37, 147-149.	0.6	18
50	Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma. PLoS Genetics, 2014, 10, e1004107.	3.5	38
51	Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes and Development, 2014, 28, 1578-1591.	5.9	87
52	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a025650-a025650.	6.2	60
53	Anaplastic rhabdomyosarcoma in <i>TP53</i> germline mutation carriers. Cancer, 2014, 120, 1068-1075.	4.1	93
54	Rictor/mTORC2 Loss in the Myf5 Lineage Reprograms Brown Fat Metabolism and Protects Mice against Obesity and Metabolic Disease. Cell Reports, 2014, 8, 256-271.	6.4	92

SIMONE HETTMER

#	Article	IF	CITATIONS
55	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. Cancer Cell, 2014, 26, 273-287.	16.8	152
56	Isolation of Progenitors that Exhibit Myogenic/Osteogenic Bipotency InÂVitro by Fluorescence-Activated Cell Sorting from Human Fetal Muscle. Stem Cell Reports, 2014, 2, 92-106.	4.8	64
57	A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development (Cambridge), 2013, 140, 2354-2364.	2.5	53
58	Mutations in Hedgehog pathway genes in fetal rhabdomyomas. Journal of Pathology, 2013, 231, 44-52.	4.5	32
59	Induction of Histiocytic Sarcoma in Mouse Skeletal Muscle. PLoS ONE, 2012, 7, e44044.	2.5	3
60	Abstract 1361: Sarcoma-relevant genetic events identified in a chimeric mouse model of sarcoma in skeletal muscle. , 2012, , .		0
61	Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proceedings of the United States of America, 2011, 108, 20002-20007.	7.1	66
62	Efficient Generation of iPS Cells from Skeletal Muscle Stem Cells. PLoS ONE, 2011, 6, e26406.	2.5	50
63	Muscling in: Uncovering the origins of rhabdomyosarcoma. Nature Medicine, 2010, 16, 171-173.	30.7	112
64	Synovial Sarcoma in Children: Imaging Features and Common Benign Mimics. American Journal of Roentgenology, 2010, 195, 1026-1032.	2.2	38
65	Cefepimeâ€induced neutropenia in a teenager. Pediatric Blood and Cancer, 2008, 51, 715-716.	1.5	8
66	Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells. Human Immunology, 2005, 66, 95-103.	2.4	24
67	Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Letters, 2005, 225, 141-149.	7.2	37
68	Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression. Cancer Research, 2003, 63, 7270-6.	0.9	25